Nephros Other Current Liab from 2010 to 2024

NEPH Stock  USD 1.51  0.01  0.67%   
Nephros' Other Current Liabilities is increasing with stable movements from year to year. Other Current Liabilities is estimated to finish at about 456.2 K this year. For the period between 2010 and 2024, Nephros, Other Current Liabilities quarterly trend regression had mean deviation of  103,559 and range of 666 K. View All Fundamentals
 
Other Current Liabilities  
First Reported
2001-12-31
Previous Quarter
77 K
Current Value
322 K
Quarterly Volatility
554.1 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nephros financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nephros' main balance sheet or income statement drivers, such as Depreciation And Amortization of 203.3 K, Interest Expense of 1.9 K or Total Revenue of 14.9 M, as well as many indicators such as Price To Sales Ratio of 2.4, Dividend Yield of 0.0144 or PTB Ratio of 3.48. Nephros financial statements analysis is a perfect complement when working with Nephros Valuation or Volatility modules.
  
Check out the analysis of Nephros Correlation against competitors.
For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.

Latest Nephros' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Nephros over the last few years. It is Nephros' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nephros' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Pretty Stable
   Other Current Liab   
       Timeline  

Nephros Other Current Liab Regression Statistics

Arithmetic Mean313,744
Geometric Mean273,629
Coefficient Of Variation47.77
Mean Deviation103,559
Median300,000
Standard Deviation149,866
Sample Variance22.5B
Range666K
R-Value0.20
Mean Square Error23.2B
R-Squared0.04
Significance0.48
Slope6,657
Total Sum of Squares314.4B

Nephros Other Current Liab History

2024456.2 K
2023312 K
2022268 K
2021448 K
2020341 K
2019300 K
2018236 K

About Nephros Financial Statements

Investors use fundamental indicators, such as Nephros' Other Current Liab, to determine how well the company is positioned to perform in the future. Although Nephros' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Other Current Liabilities312 K456.2 K

Currently Active Assets on Macroaxis

When determining whether Nephros offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nephros' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nephros Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nephros Stock:
Check out the analysis of Nephros Correlation against competitors.
For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Household Appliances space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.09)
Revenue Per Share
1.313
Quarterly Revenue Growth
(0.08)
Return On Assets
(0.08)
Return On Equity
(0.16)
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.